PROCEPT BioRobotics (MEX:PRCT) Dividend-Payout-to-FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:PRCT PROCEPT BioRobotics Corp MEX:PRCT
44 GF Score
Price MXN357.00
GF Value MXN1,386.73
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is PROCEPT BioRobotics Dividend-Payout-to-FFO?

Dividend-Payout-to-FFO only applies to REITs.

MEX:PRCT
44GF Score
PROCEPT BioRobotics Corp MEX:PRCT
Dividend-Payout-to-FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is PROCEPT BioRobotics (MEX:PRCT) Overvalued in 2026?

Based on GuruFocus' analysis, PROCEPT BioRobotics stock appears to be undervalued. The current stock price of MXN357.00 is trading 74.3% below its estimated GF Value™ of MXN1,386.73. GuruFocus considers PROCEPT BioRobotics to be Significantly Undervalued.

Key valuation signals for MEX:PRCT:

  • Dividend-Payout-to-FFO:
  • GF Value™: MXN1,386.73 vs. price of MXN357.00 (74.3% below fair value)
  • GF Score™: 44/100 with 1 warning sign

No single metric tells the full story. See the MEX:PRCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PROCEPT BioRobotics Business Description

Other Exchanges PRCT:USA
Address 150 Baytech Drive, San Jose, CA, USA, 95134
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
44GF Score

Get the complete analysis for MEX:PRCT

Dividend-Payout-to-FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN357.00
Price
MXN1,386.73
GF Value